Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
10-hydroxycamptothecin + FORMESTANE
|
DCOQX8S
|
10-hydroxycamptothecin
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
10-hydroxycamptothecin + FORMESTANE
|
DCM6PTX
|
10-hydroxycamptothecin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
ABIRATERONE + FORMESTANE
|
DCP1NA6
|
ABIRATERONE
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
ABIRATERONE + FORMESTANE
|
DCQKMC8
|
ABIRATERONE
|
Glioma (Cell Line: SF-268)
|
[4] |
|
ABIRATERONE + FORMESTANE
|
DCVFY1B
|
ABIRATERONE
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
ABIRATERONE + FORMESTANE
|
DCPJS9Y
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
ABIRATERONE + FORMESTANE
|
DC7A5SR
|
ABIRATERONE
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
ABIRATERONE + FORMESTANE
|
DCEUZ17
|
ABIRATERONE
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
ABIRATERONE + FORMESTANE
|
DCGUEEI
|
ABIRATERONE
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Acamprosate + FORMESTANE
|
DCOWL1W
|
Acamprosate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Amonafide + FORMESTANE
|
DC7QQQ8
|
Amonafide
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Amonafide + FORMESTANE
|
DC54JII
|
Amonafide
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Anastrozole + FORMESTANE
|
DCNIT92
|
Anastrozole
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Anastrozole + FORMESTANE
|
DCGAMLA
|
Anastrozole
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Anastrozole + FORMESTANE
|
DCMGUX2
|
Anastrozole
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Anastrozole + FORMESTANE
|
DC7KDPM
|
Anastrozole
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Anastrozole + FORMESTANE
|
DC3B40U
|
Anastrozole
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Anastrozole + FORMESTANE
|
DCGINAD
|
Anastrozole
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Anastrozole + FORMESTANE
|
DC4AAGR
|
Anastrozole
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Anastrozole + FORMESTANE
|
DC41T82
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
Anastrozole + FORMESTANE
|
DC8ZQ0N
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Anastrozole + FORMESTANE
|
DCL4RZY
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Anastrozole + FORMESTANE
|
DCIUPEX
|
Anastrozole
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Anastrozole + FORMESTANE
|
DCC1U82
|
Anastrozole
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Anastrozole + FORMESTANE
|
DC6I9H3
|
Anastrozole
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Anastrozole + FORMESTANE
|
DC4HGYB
|
Anastrozole
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Anastrozole + FORMESTANE
|
DCK7IB0
|
Anastrozole
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Anastrozole + FORMESTANE
|
DCWW216
|
Anastrozole
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Arfolitixorin + FORMESTANE
|
DCJ4P5U
|
Arfolitixorin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Azacitidine + FORMESTANE
|
DCKAVXG
|
Azacitidine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Azacitidine + FORMESTANE
|
DCKCJTM
|
Azacitidine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Azacitidine + FORMESTANE
|
DCKZFF0
|
Azacitidine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Azacitidine + FORMESTANE
|
DCQFV5F
|
Azacitidine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Azacitidine + FORMESTANE
|
DC69HQY
|
Azacitidine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Azacitidine + FORMESTANE
|
DCB89NI
|
Azacitidine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Azacitidine + FORMESTANE
|
DC7ZP3L
|
Azacitidine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Azacitidine + FORMESTANE
|
DCUXONY
|
Azacitidine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Azacitidine + FORMESTANE
|
DCRD9EN
|
Azacitidine
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Azacitidine + FORMESTANE
|
DC5XR27
|
Azacitidine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Azacitidine + FORMESTANE
|
DCVLUDK
|
Azacitidine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Bleomycin + FORMESTANE
|
DCFA0AK
|
Bleomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Bleomycin + FORMESTANE
|
DCBPG17
|
Bleomycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Bleomycin + FORMESTANE
|
DCUVHC4
|
Bleomycin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Bortezomib + FORMESTANE
|
DC0V9YI
|
Bortezomib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Brincidofovir + FORMESTANE
|
DC90YFG
|
Brincidofovir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Busulfan + FORMESTANE
|
DCAKJE8
|
Busulfan
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Busulfan + FORMESTANE
|
DCKU2XL
|
Busulfan
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Busulfan + FORMESTANE
|
DCA5UUM
|
Busulfan
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Busulfan + FORMESTANE
|
DCPZWMS
|
Busulfan
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Busulfan + FORMESTANE
|
DCV2S7Q
|
Busulfan
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Busulfan + FORMESTANE
|
DC53DMC
|
Busulfan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Busulfan + FORMESTANE
|
DCG9EBX
|
Busulfan
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Busulfan + FORMESTANE
|
DC5BTNT
|
Busulfan
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Busulfan + FORMESTANE
|
DCIFTSN
|
Busulfan
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Busulfan + FORMESTANE
|
DCL9ESH
|
Busulfan
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Busulfan + FORMESTANE
|
DC1ONGM
|
Busulfan
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Busulfan + FORMESTANE
|
DCTBO2K
|
Busulfan
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Busulfan + FORMESTANE
|
DCWSZ9N
|
Busulfan
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Busulfan + FORMESTANE
|
DC9DVP6
|
Busulfan
|
Glioma (Cell Line: SF-539)
|
[4] |
|
Busulfan + FORMESTANE
|
DCG6N37
|
Busulfan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Busulfan + FORMESTANE
|
DC304KY
|
Busulfan
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Busulfan + FORMESTANE
|
DCU6VSB
|
Busulfan
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Busulfan + FORMESTANE
|
DCPI0H0
|
Busulfan
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Busulfan + FORMESTANE
|
DCOGRNR
|
Busulfan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Busulfan + FORMESTANE
|
DCQGM53
|
Busulfan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Cabazitaxel + FORMESTANE
|
DCPTE6O
|
Cabazitaxel
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Cabazitaxel + FORMESTANE
|
DCXLKWU
|
Cabazitaxel
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Cabazitaxel + FORMESTANE
|
DC51DHZ
|
Cabazitaxel
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Crizotinib + FORMESTANE
|
DCKC7ZO
|
Crizotinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Crizotinib + FORMESTANE
|
DC8T8MD
|
Crizotinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Crizotinib + FORMESTANE
|
DCNCQSX
|
Crizotinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Crizotinib + FORMESTANE
|
DCMD84O
|
Crizotinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
Crizotinib + FORMESTANE
|
DCWDIPB
|
Crizotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Crizotinib + FORMESTANE
|
DCC8LTI
|
Crizotinib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Crizotinib + FORMESTANE
|
DCR9SF4
|
Crizotinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Crizotinib + FORMESTANE
|
DCMYPYZ
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Dacarbazine + FORMESTANE
|
DCBHHEL
|
Dacarbazine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Dacarbazine + FORMESTANE
|
DCF1W2X
|
Dacarbazine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Dacarbazine + FORMESTANE
|
DC5LECO
|
Dacarbazine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Dacarbazine + FORMESTANE
|
DC7807B
|
Dacarbazine
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Dacarbazine + FORMESTANE
|
DCNGJ88
|
Dacarbazine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Dasatinib + FORMESTANE
|
DC0JCZQ
|
Dasatinib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Dasatinib + FORMESTANE
|
DCJI8FC
|
Dasatinib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Dasatinib + FORMESTANE
|
DC9CE0O
|
Dasatinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Dasatinib + FORMESTANE
|
DCMM2IJ
|
Dasatinib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Dasatinib + FORMESTANE
|
DCMZ5N8
|
Dasatinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Dexrazoxane + FORMESTANE
|
DCITZS2
|
Dexrazoxane
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Dexrazoxane + FORMESTANE
|
DCFC2AE
|
Dexrazoxane
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Dexrazoxane + FORMESTANE
|
DC648R7
|
Dexrazoxane
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Dexrazoxane + FORMESTANE
|
DCD2UVP
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
DFN-15 + FORMESTANE
|
DCRBZSK
|
DFN-15
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
DFN-15 + FORMESTANE
|
DCD11NF
|
DFN-15
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
DFN-15 + FORMESTANE
|
DCRZMB8
|
DFN-15
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
DFN-15 + FORMESTANE
|
DCTME0M
|
DFN-15
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
DFN-15 + FORMESTANE
|
DCQ78RY
|
DFN-15
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Digitoxin + FORMESTANE
|
DC1LW86
|
Digitoxin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Digitoxin + FORMESTANE
|
DCK2JKL
|
Digitoxin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Digitoxin + FORMESTANE
|
DCFFF9X
|
Digitoxin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Docetaxel + FORMESTANE
|
DCBRSH2
|
Docetaxel
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Epirubicin + FORMESTANE
|
DC7AE2Z
|
Epirubicin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Epirubicin + FORMESTANE
|
DC0UCGB
|
Epirubicin
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Epirubicin + FORMESTANE
|
DCYDDCR
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Epirubicin + FORMESTANE
|
DCOAH4G
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Epirubicin + FORMESTANE
|
DCO0MF2
|
Epirubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Epirubicin + FORMESTANE
|
DCOQGMG
|
Epirubicin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Epirubicin + FORMESTANE
|
DC80I8E
|
Epirubicin
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Estramustine + FORMESTANE
|
DCIDBD9
|
Estramustine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Estramustine + FORMESTANE
|
DCQETTW
|
Estramustine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Estramustine + FORMESTANE
|
DCW6Q0R
|
Estramustine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Estramustine + FORMESTANE
|
DCF9JZN
|
Estramustine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
Estramustine + FORMESTANE
|
DCH0NXT
|
Estramustine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Estramustine + FORMESTANE
|
DCRTG1K
|
Estramustine
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Estramustine + FORMESTANE
|
DCC5T5D
|
Estramustine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Estramustine + FORMESTANE
|
DC461Y6
|
Estramustine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Fenoprofen + FORMESTANE
|
DC6U9GC
|
Fenoprofen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Fludarabine + FORMESTANE
|
DCARR3L
|
Fludarabine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Fludarabine + FORMESTANE
|
DCDXKV9
|
Fludarabine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Fludarabine + FORMESTANE
|
DCDOCLJ
|
Fludarabine
|
Glioma (Cell Line: SF-268)
|
[4] |
|
FORMESTANE + Pentostatin
|
DCC7ATE
|
Pentostatin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
FORMESTANE + Pentostatin
|
DC8V3K9
|
Pentostatin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
FORMESTANE + Pentostatin
|
DCDSRGS
|
Pentostatin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
FORMESTANE + Pentostatin
|
DCXA4BN
|
Pentostatin
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
FORMESTANE + Pentostatin
|
DCGE3UU
|
Pentostatin
|
Glioma (Cell Line: SF-539)
|
[4] |
|
FORMESTANE + Pentostatin
|
DCRCCVT
|
Pentostatin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
FORMESTANE + Pentostatin
|
DCC22L8
|
Pentostatin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
FORMESTANE + Pentostatin
|
DCO0WTC
|
Pentostatin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
FORMESTANE + Pentostatin
|
DCZTJDI
|
Pentostatin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
FORMESTANE + Baclofen
|
DCQG2CN
|
Baclofen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Bepridil
|
DC5PVYP
|
Bepridil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Gefitinib
|
DC1AGWZ
|
Gefitinib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Dantrolene
|
DCQ3WYL
|
Dantrolene
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Hepzato
|
DC39FMM
|
Hepzato
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
FORMESTANE + Hepzato
|
DCJPLAL
|
Hepzato
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
FORMESTANE + Ixabepilone
|
DCPVV9S
|
Ixabepilone
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
FORMESTANE + Dactinomycin
|
DCD748B
|
Dactinomycin
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
FORMESTANE + Dactinomycin
|
DCG0859
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
FORMESTANE + Dactinomycin
|
DCWV0FG
|
Dactinomycin
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
FORMESTANE + Dactinomycin
|
DCGFS86
|
Dactinomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
FORMESTANE + Epinephrine
|
DCA3RY8
|
Epinephrine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + PMID28460551-Compound-2
|
DCCEBQP
|
PMID28460551-Compound-2
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
FORMESTANE + PMID28460551-Compound-2
|
DC1S2JM
|
PMID28460551-Compound-2
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Cyclophosphamide
|
DCIB2CV
|
Cyclophosphamide
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
FORMESTANE + Cyclophosphamide
|
DCSFSPW
|
Cyclophosphamide
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
FORMESTANE + Cyclophosphamide
|
DC9UU9J
|
Cyclophosphamide
|
Glioma (Cell Line: SF-268)
|
[4] |
|
FORMESTANE + Cyclophosphamide
|
DC4L9M8
|
Cyclophosphamide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
FORMESTANE + Cyclophosphamide
|
DCFDU02
|
Cyclophosphamide
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
FORMESTANE + Cyclophosphamide
|
DCPSM29
|
Cyclophosphamide
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
FORMESTANE + Methotrexate
|
DCWC3NF
|
Methotrexate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Methotrexate
|
DCW84T6
|
Methotrexate
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
FORMESTANE + Isoniazid
|
DCHDF9Z
|
Isoniazid
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
FORMESTANE + Isoniazid
|
DCITE04
|
Isoniazid
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
FORMESTANE + Isoniazid
|
DC8R8B8
|
Isoniazid
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
FORMESTANE + Isoniazid
|
DC2WWM3
|
Isoniazid
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
FORMESTANE + Isoniazid
|
DCUVIL2
|
Isoniazid
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
FORMESTANE + Isoniazid
|
DCIEZYE
|
Isoniazid
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
FORMESTANE + Vinblastine
|
DCI0E0C
|
Vinblastine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Arsenic trioxide
|
DCQ1SQR
|
Arsenic trioxide
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
FORMESTANE + Arsenic trioxide
|
DC7P6WF
|
Arsenic trioxide
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
FORMESTANE + Arsenic trioxide
|
DC0RGBD
|
Arsenic trioxide
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
FORMESTANE + Arsenic trioxide
|
DC3ITMB
|
Arsenic trioxide
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
FORMESTANE + Nilotinib
|
DCDPPIO
|
Nilotinib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
FORMESTANE + Nilotinib
|
DCEPP6I
|
Nilotinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
FORMESTANE + Nilotinib
|
DCNVPAU
|
Nilotinib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
FORMESTANE + Nilotinib
|
DC8DLYO
|
Nilotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
FORMESTANE + Triapine
|
DC9TIOD
|
Triapine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Topetecan
|
DCYZA98
|
Topetecan
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
FORMESTANE + Pralatrexate
|
DCDIPL0
|
Pralatrexate
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
FORMESTANE + Pralatrexate
|
DCFRSRH
|
Pralatrexate
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
FORMESTANE + Pralatrexate
|
DCU1IYA
|
Pralatrexate
|
Glioma (Cell Line: SF-295)
|
[4] |
|
FORMESTANE + Pralatrexate
|
DCVGK60
|
Pralatrexate
|
Glioma (Cell Line: SF-268)
|
[4] |
|
FORMESTANE + Pralatrexate
|
DCXPSQ0
|
Pralatrexate
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
FORMESTANE + Pralatrexate
|
DC6SNWM
|
Pralatrexate
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
FORMESTANE + IT-141
|
DCFSLY4
|
IT-141
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Metyrosine
|
DC9LKW0
|
Metyrosine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Terameprocol
|
DC6R6Y6
|
Terameprocol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Ifosfamide
|
DCYLU8X
|
Ifosfamide
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
FORMESTANE + Ifosfamide
|
DC323FP
|
Ifosfamide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
FORMESTANE + Ifosfamide
|
DCHM719
|
Ifosfamide
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
FORMESTANE + Ifosfamide
|
DCD13RS
|
Ifosfamide
|
Glioma (Cell Line: SF-539)
|
[4] |
|
FORMESTANE + Ifosfamide
|
DCF6JYT
|
Ifosfamide
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
FORMESTANE + Ifosfamide
|
DCODJVW
|
Ifosfamide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
FORMESTANE + Ifosfamide
|
DCCDHI7
|
Ifosfamide
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
FORMESTANE + Docetaxel
|
DCTJYTW
|
Docetaxel
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
FORMESTANE + Raloxifene
|
DC69LGE
|
Raloxifene
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
FORMESTANE + Raloxifene
|
DCBSMMK
|
Raloxifene
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
FORMESTANE + Raloxifene
|
DCXZIOD
|
Raloxifene
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
FORMESTANE + Raloxifene
|
DCCE723
|
Raloxifene
|
Glioma (Cell Line: SF-539)
|
[4] |
|
FORMESTANE + Raloxifene
|
DCJXGER
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
FORMESTANE + Bendamustine hydrochloride
|
DCN3658
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
FORMESTANE + Bendamustine hydrochloride
|
DC8H5Q7
|
Bendamustine hydrochloride
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
FORMESTANE + Bendamustine hydrochloride
|
DCAEXDE
|
Bendamustine hydrochloride
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
FORMESTANE + Bendamustine hydrochloride
|
DCHI7XQ
|
Bendamustine hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
FORMESTANE + Bendamustine hydrochloride
|
DCKJ12F
|
Bendamustine hydrochloride
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
FORMESTANE + Mitomycin
|
DC3FKPK
|
Mitomycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
FORMESTANE + Mitomycin
|
DCU4MNN
|
Mitomycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
FORMESTANE + Mitomycin
|
DC4PTSU
|
Mitomycin
|
Glioma (Cell Line: SF-295)
|
[4] |
|
FORMESTANE + Mitomycin
|
DCWMQWG
|
Mitomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
FORMESTANE + Mitomycin
|
DCTUDFZ
|
Mitomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
FORMESTANE + Mitomycin
|
DCSC5LK
|
Mitomycin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
FORMESTANE + Diphenidol
|
DCF1339
|
Diphenidol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Tolvaptan
|
DCPD827
|
Tolvaptan
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Niclosamide
|
DCSIYBR
|
Niclosamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + PF-02545920
|
DCKEYIL
|
PF-02545920
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Altretamine
|
DC2NBLR
|
Altretamine
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
FORMESTANE + Altretamine
|
DCFD1YP
|
Altretamine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
FORMESTANE + Altretamine
|
DCWNR0M
|
Altretamine
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
FORMESTANE + Altretamine
|
DCYEN7C
|
Altretamine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
FORMESTANE + Altretamine
|
DCWO4WK
|
Altretamine
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
FORMESTANE + Altretamine
|
DC73DM0
|
Altretamine
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
FORMESTANE + Tiagabine
|
DC5B8MU
|
Tiagabine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Idarubicin
|
DCAFMCN
|
Idarubicin
|
Glioblastoma? (Cell Line: T98G)
|
[4] |
|
FORMESTANE + Darunavir
|
DC2XVIF
|
Darunavir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Bortezomib
|
DCG4NQ7
|
Bortezomib
|
Glioma (Cell Line: SF-539)
|
[4] |
|
FORMESTANE + Trimethobenzamide
|
DCM0S7G
|
Trimethobenzamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Chlorambucil
|
DCOEHCU
|
Chlorambucil
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
FORMESTANE + Chlorambucil
|
DCV98QQ
|
Chlorambucil
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
FORMESTANE + Chlorambucil
|
DCS3MSA
|
Chlorambucil
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
FORMESTANE + Chlorambucil
|
DCH2DNP
|
Chlorambucil
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
FORMESTANE + Chlorambucil
|
DC2SPFR
|
Chlorambucil
|
Glioma (Cell Line: SF-295)
|
[4] |
|
FORMESTANE + Chlorambucil
|
DCKHO8U
|
Chlorambucil
|
Glioma (Cell Line: SF-539)
|
[4] |
|
FORMESTANE + Chlorambucil
|
DCNO7UZ
|
Chlorambucil
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
FORMESTANE + Chlorambucil
|
DC9NCNE
|
Chlorambucil
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
FORMESTANE + ER819762
|
DC12KC9
|
ER819762
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
FORMESTANE + ER819762
|
DC4F4Q3
|
ER819762
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
FORMESTANE + ER819762
|
DCT92E2
|
ER819762
|
Glioma (Cell Line: SF-539)
|
[4] |
|
FORMESTANE + ER819762
|
DCXJBJA
|
ER819762
|
Glioma (Cell Line: SF-295)
|
[4] |
|
FORMESTANE + ER819762
|
DC222CG
|
ER819762
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
FORMESTANE + ER819762
|
DCXH73N
|
ER819762
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
FORMESTANE + ER819762
|
DC523TP
|
ER819762
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
FORMESTANE + Hyodeoxycholic acid
|
DC5XG3S
|
Hyodeoxycholic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Asenapine
|
DC2BYZJ
|
Asenapine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Quinine
|
DCMT68V
|
Quinine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Azacitidine
|
DCZ7Y2O
|
Azacitidine
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
FORMESTANE + Pomalidomide
|
DCLKJYT
|
Pomalidomide
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
FORMESTANE + Pomalidomide
|
DCPT35K
|
Pomalidomide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Pomalidomide
|
DCVH1KL
|
Pomalidomide
|
Glioma (Cell Line: SF-539)
|
[4] |
|
FORMESTANE + Pomalidomide
|
DC7367P
|
Pomalidomide
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
FORMESTANE + Mercaptopurine
|
DCHYWJJ
|
Mercaptopurine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
FORMESTANE + Mercaptopurine
|
DCZIVWJ
|
Mercaptopurine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
FORMESTANE + Mercaptopurine
|
DCOUFLI
|
Mercaptopurine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
FORMESTANE + Mercaptopurine
|
DCU78Z2
|
Mercaptopurine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
FORMESTANE + Mercaptopurine
|
DCJ8UP5
|
Mercaptopurine
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
FORMESTANE + Mercaptopurine
|
DC89HTK
|
Mercaptopurine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
FORMESTANE + Mercaptopurine
|
DCYI37F
|
Mercaptopurine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
FORMESTANE + Mepacrine
|
DC3G3Z0
|
Mepacrine
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
FORMESTANE + Mepacrine
|
DCPY9AJ
|
Mepacrine
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
FORMESTANE + Mepacrine
|
DCKAEF2
|
Mepacrine
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
FORMESTANE + Mepacrine
|
DCW4N4V
|
Mepacrine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
FORMESTANE + Mepacrine
|
DCYU0R5
|
Mepacrine
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
FORMESTANE + Mepacrine
|
DCYP8MC
|
Mepacrine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
FORMESTANE + Mepacrine
|
DC894JO
|
Mepacrine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
FORMESTANE + Mepacrine
|
DCQR1US
|
Mepacrine
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
FORMESTANE + Mepacrine
|
DCTQ56Z
|
Mepacrine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
FORMESTANE + Mepacrine
|
DCWJX2R
|
Mepacrine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
FORMESTANE + Mepacrine
|
DCH6WPO
|
Mepacrine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
FORMESTANE + Mepacrine
|
DCWS2NO
|
Mepacrine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
FORMESTANE + Mepacrine
|
DC1P6IH
|
Mepacrine
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
FORMESTANE + Mepacrine
|
DC8ZT0F
|
Mepacrine
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
FORMESTANE + Mepacrine
|
DC0O5GW
|
Mepacrine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
FORMESTANE + Mepacrine
|
DCPW03Q
|
Mepacrine
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
FORMESTANE + Auranofin
|
DCRLRZJ
|
Auranofin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + PMID28870136-Compound-43
|
DCARGKD
|
PMID28870136-Compound-43
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
FORMESTANE + PMID28870136-Compound-43
|
DC47WHX
|
PMID28870136-Compound-43
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
FORMESTANE + Aminolevulinic Acid Hydrochloride
|
DC5GHNO
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
FORMESTANE + Aminolevulinic Acid Hydrochloride
|
DCREEZQ
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
FORMESTANE + Aminolevulinic Acid Hydrochloride
|
DCCMIO0
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
FORMESTANE + Aminolevulinic Acid Hydrochloride
|
DCXC3ZT
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
FORMESTANE + Aminolevulinic Acid Hydrochloride
|
DCIJ5R8
|
Aminolevulinic Acid Hydrochloride
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
FORMESTANE + Aminolevulinic Acid Hydrochloride
|
DCTY4T4
|
Aminolevulinic Acid Hydrochloride
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
FORMESTANE + Aminolevulinic Acid Hydrochloride
|
DCCAL30
|
Aminolevulinic Acid Hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
FORMESTANE + Aminolevulinic Acid Hydrochloride
|
DCOS3SZ
|
Aminolevulinic Acid Hydrochloride
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
FORMESTANE + Aminolevulinic Acid Hydrochloride
|
DCQWFKN
|
Aminolevulinic Acid Hydrochloride
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
FORMESTANE + Aminolevulinic Acid Hydrochloride
|
DC2CZ2L
|
Aminolevulinic Acid Hydrochloride
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
FORMESTANE + Cerivastatin
|
DC70V7U
|
Cerivastatin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Raltegravir
|
DCJ8GK4
|
Raltegravir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
FORMESTANE + Hepzato
|
DCEZ9F4
|
Hepzato
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
FORMESTANE + PMID28460551-Compound-2
|
DCHFF2K
|
PMID28460551-Compound-2
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
FORMESTANE + PMID28460551-Compound-2
|
DCS3OV8
|
PMID28460551-Compound-2
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
FORMESTANE + Cyclophosphamide
|
DCIKUF4
|
Cyclophosphamide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
FORMESTANE + Cyclophosphamide
|
DC56VIZ
|
Cyclophosphamide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
FORMESTANE + Topetecan
|
DCWVJ5A
|
Topetecan
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
FORMESTANE + Altretamine
|
DC84N2E
|
Altretamine
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
FORMESTANE + Bortezomib
|
DCA06OF
|
Bortezomib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
FORMESTANE + Chlorambucil
|
DCGQMCI
|
Chlorambucil
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
FORMESTANE + Mercaptopurine
|
DCI5HF2
|
Mercaptopurine
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
FORMESTANE + Mepacrine
|
DC58O09
|
Mepacrine
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Fulvestrant + FORMESTANE
|
DCCN3FN
|
Fulvestrant
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Fulvestrant + FORMESTANE
|
DC08VW4
|
Fulvestrant
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Fulvestrant + FORMESTANE
|
DC391GH
|
Fulvestrant
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
Fulvestrant + FORMESTANE
|
DCII7H9
|
Fulvestrant
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Fulvestrant + FORMESTANE
|
DC441YS
|
Fulvestrant
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Gefitinib + FORMESTANE
|
DCKQYT4
|
Gefitinib
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Gefitinib + FORMESTANE
|
DCXM1BM
|
Gefitinib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Gefitinib + FORMESTANE
|
DCXVOAQ
|
Gefitinib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Gefitinib + FORMESTANE
|
DC0KV9D
|
Gefitinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Gefitinib + FORMESTANE
|
DCW4RX1
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
Gefitinib + FORMESTANE
|
DCAC4BQ
|
Gefitinib
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Gefitinib + FORMESTANE
|
DCOZ37C
|
Gefitinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
Hepzato + FORMESTANE
|
DC5XHOH
|
Hepzato
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Hepzato + FORMESTANE
|
DCN3DRM
|
Hepzato
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Hepzato + FORMESTANE
|
DCO3PR3
|
Hepzato
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Hepzato + FORMESTANE
|
DCUX3W9
|
Hepzato
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Hepzato + FORMESTANE
|
DC2WOP6
|
Hepzato
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Hepzato + FORMESTANE
|
DCK18RJ
|
Hepzato
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Idarubicin + FORMESTANE
|
DCGV3ON
|
Idarubicin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Imatinib + FORMESTANE
|
DCVW9TL
|
Imatinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Imatinib + FORMESTANE
|
DCP5S58
|
Imatinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Imatinib + FORMESTANE
|
DCN8Y7Y
|
Imatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + FORMESTANE
|
DCIQWTC
|
Indazole derivative 5
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Indazole derivative 5 + FORMESTANE
|
DCCREDV
|
Indazole derivative 5
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + FORMESTANE
|
DCNRZ8B
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + FORMESTANE
|
DCZXIPW
|
Indazole derivative 5
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + FORMESTANE
|
DCTF86O
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + FORMESTANE
|
DC94PNA
|
Indazole derivative 5
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + FORMESTANE
|
DCCAOBU
|
Indazole derivative 5
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + FORMESTANE
|
DC7TVHL
|
Indazole derivative 5
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
JNK-IN-8 + FORMESTANE
|
DCWTGBJ
|
JNK-IN-8
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
JNK-IN-8 + FORMESTANE
|
DCRLMGR
|
JNK-IN-8
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
JNK-IN-8 + FORMESTANE
|
DCZL2CP
|
JNK-IN-8
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
JNK-IN-8 + FORMESTANE
|
DCPW4QF
|
JNK-IN-8
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Lapatinib + FORMESTANE
|
DCBH5E1
|
Lapatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Lapatinib + FORMESTANE
|
DCFQ6Q9
|
Lapatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Lapatinib + FORMESTANE
|
DC06ESE
|
Lapatinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Lapatinib + FORMESTANE
|
DCX1M57
|
Lapatinib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Lapatinib + FORMESTANE
|
DCD6CB8
|
Lapatinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Leflunomide + FORMESTANE
|
DC22QW7
|
Leflunomide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Lenalidomide + FORMESTANE
|
DC5J9F0
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Lenalidomide + FORMESTANE
|
DCNRNL7
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Lenalidomide + FORMESTANE
|
DCIL3TN
|
Lenalidomide
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Lenalidomide + FORMESTANE
|
DCOPZXG
|
Lenalidomide
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Lenalidomide + FORMESTANE
|
DC5WHAG
|
Lenalidomide
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Letrozole + FORMESTANE
|
DCPB36T
|
Letrozole
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Letrozole + FORMESTANE
|
DCA4Z35
|
Letrozole
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Letrozole + FORMESTANE
|
DC8H2G6
|
Letrozole
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Letrozole + FORMESTANE
|
DCFLN1E
|
Letrozole
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Levamisole + FORMESTANE
|
DCD9OS7
|
Levamisole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
LIAROZOLE + FORMESTANE
|
DCJB3ZY
|
LIAROZOLE
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
LIAROZOLE + FORMESTANE
|
DCV9LIH
|
LIAROZOLE
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
LIAROZOLE + FORMESTANE
|
DCBTJP5
|
LIAROZOLE
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
LIAROZOLE + FORMESTANE
|
DCZQYYP
|
LIAROZOLE
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Maprotiline + FORMESTANE
|
DC1GU3Q
|
Maprotiline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Maraviroc + FORMESTANE
|
DC0AGBX
|
Maraviroc
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Mechlorethamine + FORMESTANE
|
DC284KS
|
Mechlorethamine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Metaxalone + FORMESTANE
|
DCCBZOE
|
Metaxalone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Methylene blue + FORMESTANE
|
DCJAET8
|
Methylene blue
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Methylergonovine + FORMESTANE
|
DCQX7RC
|
Methylergonovine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Mycophenolic acid + FORMESTANE
|
DCILXL3
|
Mycophenolic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Nabilone + FORMESTANE
|
DC4NIK3
|
Nabilone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Nilotinib + FORMESTANE
|
DCVYE6J
|
Nilotinib
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Olmesartan medoxomil + FORMESTANE
|
DCZ568U
|
Olmesartan medoxomil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Oseltamivir + FORMESTANE
|
DCRG65Q
|
Oseltamivir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Pamidronate + FORMESTANE
|
DC5TH7B
|
Pamidronate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Picoplatin + FORMESTANE
|
DCZAIUK
|
Picoplatin
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Picoplatin + FORMESTANE
|
DCJK7CA
|
Picoplatin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Plicamycin + FORMESTANE
|
DCHRD21
|
Plicamycin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Plicamycin + FORMESTANE
|
DCBLS4D
|
Plicamycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Plicamycin + FORMESTANE
|
DCK7AYS
|
Plicamycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Plicamycin + FORMESTANE
|
DCV9LIJ
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Plicamycin + FORMESTANE
|
DCUYZ67
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Plicamycin + FORMESTANE
|
DC3S8QV
|
Plicamycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Plicamycin + FORMESTANE
|
DC7Y5DS
|
Plicamycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DCVU9VI
|
PMID28460551-Compound-2
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DCUUBOT
|
PMID28460551-Compound-2
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DCL7PVS
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DC7BXZ2
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DCCGCHL
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DCJZSID
|
PMID28460551-Compound-2
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
PMID28460551-Compound-2 + FORMESTANE
|
DCLJMOU
|
PMID28460551-Compound-2
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Raloxifene + FORMESTANE
|
DCQRD2Y
|
Raloxifene
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Raloxifene + FORMESTANE
|
DCCGR6B
|
Raloxifene
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Raloxifene + FORMESTANE
|
DC1VX47
|
Raloxifene
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCUAT12
|
Raloxifene
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCHHE7F
|
Raloxifene
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCDN2V3
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCY8LAA
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCS1PIP
|
Raloxifene
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCPVCOJ
|
Raloxifene
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Raloxifene + FORMESTANE
|
DCXZ1BI
|
Raloxifene
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Raloxifene + FORMESTANE
|
DCPIVDO
|
Raloxifene
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Raloxifene + FORMESTANE
|
DC49AGS
|
Raloxifene
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Raloxifene + FORMESTANE
|
DCYAIBA
|
Raloxifene
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Raloxifene + FORMESTANE
|
DC1XSPQ
|
Raloxifene
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Raloxifene + FORMESTANE
|
DC2LU63
|
Raloxifene
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Raloxifene + FORMESTANE
|
DCQEQF6
|
Raloxifene
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Raloxifene + FORMESTANE
|
DC1YPOS
|
Raloxifene
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Raloxifene + FORMESTANE
|
DCT91SE
|
Raloxifene
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Raloxifene + FORMESTANE
|
DCIUHQJ
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Raloxifene + FORMESTANE
|
DCD213X
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Raloxifene + FORMESTANE
|
DC4IUXQ
|
Raloxifene
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Raloxifene + FORMESTANE
|
DCYID7W
|
Raloxifene
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Raloxifene + FORMESTANE
|
DC599BF
|
Raloxifene
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Romidepsin + FORMESTANE
|
DC7Y3CJ
|
Romidepsin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Ruxolitinib + FORMESTANE
|
DC5GUD4
|
Ruxolitinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Ruxolitinib + FORMESTANE
|
DC450B3
|
Ruxolitinib
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Ruxolitinib + FORMESTANE
|
DCYGK2E
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Ruxolitinib + FORMESTANE
|
DC21T4O
|
Ruxolitinib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Ruxolitinib + FORMESTANE
|
DCTE6K9
|
Ruxolitinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Ruxolitinib + FORMESTANE
|
DC4WBOO
|
Ruxolitinib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Ruxolitinib + FORMESTANE
|
DCVWSPK
|
Ruxolitinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
SCH 727965 + FORMESTANE
|
DCQ0SM4
|
SCH 727965
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
SCH 727965 + FORMESTANE
|
DCB9XNJ
|
SCH 727965
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
SCH 727965 + FORMESTANE
|
DC61U85
|
SCH 727965
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
SCH 727965 + FORMESTANE
|
DC4TL3L
|
SCH 727965
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Sirolimus + FORMESTANE
|
DCH2YP8
|
Sirolimus
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Sirolimus + FORMESTANE
|
DCPIZM8
|
Sirolimus
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Sirolimus + FORMESTANE
|
DCI3SR0
|
Sirolimus
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Sirolimus + FORMESTANE
|
DCQBNI8
|
Sirolimus
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Sirolimus + FORMESTANE
|
DCWFSE8
|
Sirolimus
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Sirolimus + FORMESTANE
|
DCFMSDH
|
Sirolimus
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Sirolimus + FORMESTANE
|
DCGG62H
|
Sirolimus
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Sirolimus + FORMESTANE
|
DCJ7KCY
|
Sirolimus
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Sirolimus + FORMESTANE
|
DCMM3JL
|
Sirolimus
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Sorafenib + FORMESTANE
|
DCTGXWT
|
Sorafenib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Sorafenib + FORMESTANE
|
DCZVTT8
|
Sorafenib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
SY-1425 + FORMESTANE
|
DCNCTYE
|
SY-1425
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
SY-1425 + FORMESTANE
|
DCYO3LA
|
SY-1425
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
SY-1425 + FORMESTANE
|
DCWZGUJ
|
SY-1425
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
SY-1425 + FORMESTANE
|
DCZZBPH
|
SY-1425
|
Glioma (Cell Line: SF-295)
|
[4] |
|
SY-1425 + FORMESTANE
|
DCQ2LX2
|
SY-1425
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Taxol + FORMESTANE
|
DCI9681
|
Taxol
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Taxol + FORMESTANE
|
DCAW6FH
|
Taxol
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Taxol + FORMESTANE
|
DCSZ8W8
|
Taxol
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Taxol + FORMESTANE
|
DC53G4J
|
Taxol
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Taxol + FORMESTANE
|
DCWPGAQ
|
Taxol
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Taxol + FORMESTANE
|
DCPTPIC
|
Taxol
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
TEM + FORMESTANE
|
DCOL3RR
|
TEM
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
TEM + FORMESTANE
|
DCLSU8Z
|
TEM
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
TEM + FORMESTANE
|
DCL9FZW
|
TEM
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
TEM + FORMESTANE
|
DCTBONO
|
TEM
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
TEM + FORMESTANE
|
DC7XHSW
|
TEM
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
TEM + FORMESTANE
|
DCBE6I8
|
TEM
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Terameprocol + FORMESTANE
|
DCI7XJI
|
Terameprocol
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Terameprocol + FORMESTANE
|
DCDK4FE
|
Terameprocol
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Terameprocol + FORMESTANE
|
DCQ06SU
|
Terameprocol
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Terameprocol + FORMESTANE
|
DCMXN65
|
Terameprocol
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
Terameprocol + FORMESTANE
|
DC4CMM2
|
Terameprocol
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Terameprocol + FORMESTANE
|
DCBT0OR
|
Terameprocol
|
Glioma (Cell Line: SF-295)
|
[4] |
|
Terameprocol + FORMESTANE
|
DCI323K
|
Terameprocol
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Terameprocol + FORMESTANE
|
DCZW91A
|
Terameprocol
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Terameprocol + FORMESTANE
|
DCQ5KCF
|
Terameprocol
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Terameprocol + FORMESTANE
|
DCTGLTL
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Terameprocol + FORMESTANE
|
DCQEH2M
|
Terameprocol
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Terameprocol + FORMESTANE
|
DC23I9R
|
Terameprocol
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Terameprocol + FORMESTANE
|
DCU7YSO
|
Terameprocol
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Terameprocol + FORMESTANE
|
DCQ01SW
|
Terameprocol
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Terameprocol + FORMESTANE
|
DCOY3T3
|
Terameprocol
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Terameprocol + FORMESTANE
|
DCCH7JN
|
Terameprocol
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Terameprocol + FORMESTANE
|
DCUOXAK
|
Terameprocol
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Terameprocol + FORMESTANE
|
DCP5MTL
|
Terameprocol
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Terameprocol + FORMESTANE
|
DCCJYXM
|
Terameprocol
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Terazosin + FORMESTANE
|
DC3H0O9
|
Terazosin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Testolactone + FORMESTANE
|
DCBJEW1
|
Testolactone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Thioguanine + FORMESTANE
|
DCS06J3
|
Thioguanine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Thioguanine + FORMESTANE
|
DCE3DX4
|
Thioguanine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Thioguanine + FORMESTANE
|
DCMJX8A
|
Thioguanine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Thioguanine + FORMESTANE
|
DCWTRQ5
|
Thioguanine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Thioguanine + FORMESTANE
|
DCFJ487
|
Thioguanine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Thioguanine + FORMESTANE
|
DCM7I9J
|
Thioguanine
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Topotecan + FORMESTANE
|
DCIBCIY
|
Topotecan
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Topotecan + FORMESTANE
|
DCTYCRH
|
Topotecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Topotecan + FORMESTANE
|
DC14WDK
|
Topotecan
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Topotecan + FORMESTANE
|
DCLDC9L
|
Topotecan
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Topotecan + FORMESTANE
|
DC4ZZLP
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Topotecan + FORMESTANE
|
DCVM5Y8
|
Topotecan
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Topotecan + FORMESTANE
|
DCJR6PN
|
Topotecan
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Topotecan + FORMESTANE
|
DC1C0XW
|
Topotecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Topotecan + FORMESTANE
|
DCT6INL
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Topotecan + FORMESTANE
|
DC187FX
|
Topotecan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Topotecan + FORMESTANE
|
DCR1TP8
|
Topotecan
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Topotecan + FORMESTANE
|
DCSX4TJ
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Topotecan + FORMESTANE
|
DC1EN9T
|
Topotecan
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Topotecan + FORMESTANE
|
DC8GRPV
|
Topotecan
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Triapine + FORMESTANE
|
DC9W1C0
|
Triapine
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Triapine + FORMESTANE
|
DCZ4GDU
|
Triapine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Triapine + FORMESTANE
|
DCGOZV9
|
Triapine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Triapine + FORMESTANE
|
DCH7Y6J
|
Triapine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Triapine + FORMESTANE
|
DCGT1Q5
|
Triapine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Triapine + FORMESTANE
|
DC27BAA
|
Triapine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Triapine + FORMESTANE
|
DCYW6TR
|
Triapine
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Triapine + FORMESTANE
|
DCW8FPY
|
Triapine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Triapine + FORMESTANE
|
DCYY2SG
|
Triapine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Triapine + FORMESTANE
|
DCOKGQ2
|
Triapine
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Triapine + FORMESTANE
|
DC3RCR1
|
Triapine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Trifluridine + FORMESTANE
|
DC79BFX
|
Trifluridine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Trifluridine + FORMESTANE
|
DCNZ4BD
|
Trifluridine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Trifluridine + FORMESTANE
|
DCDPMU3
|
Trifluridine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Trifluridine + FORMESTANE
|
DC579RX
|
Trifluridine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Trifluridine + FORMESTANE
|
DCRRNG7
|
Trifluridine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Triiodothyronine + FORMESTANE
|
DC4TZU6
|
Triiodothyronine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Ursodeoxycholic acid + FORMESTANE
|
DCJDRIP
|
Ursodeoxycholic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[4] |
|
Valrubicin + FORMESTANE
|
DC8JU71
|
Valrubicin
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Valrubicin + FORMESTANE
|
DCBDP2O
|
Valrubicin
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Valrubicin + FORMESTANE
|
DCWMNIP
|
Valrubicin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Valrubicin + FORMESTANE
|
DCQBZDC
|
Valrubicin
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Valrubicin + FORMESTANE
|
DCPIJEX
|
Valrubicin
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Valrubicin + FORMESTANE
|
DCBI8JR
|
Valrubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Valrubicin + FORMESTANE
|
DCLX43N
|
Valrubicin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Valrubicin + FORMESTANE
|
DCEDY43
|
Valrubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Valrubicin + FORMESTANE
|
DCITBN0
|
Valrubicin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Valrubicin + FORMESTANE
|
DCSXK71
|
Valrubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Valrubicin + FORMESTANE
|
DC0DDIK
|
Valrubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Valrubicin + FORMESTANE
|
DC0IM15
|
Valrubicin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Valrubicin + FORMESTANE
|
DCGI67H
|
Valrubicin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Valrubicin + FORMESTANE
|
DCIBCYP
|
Valrubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Valrubicin + FORMESTANE
|
DCPIC89
|
Valrubicin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Valrubicin + FORMESTANE
|
DCUZ8D1
|
Valrubicin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Valrubicin + FORMESTANE
|
DC3PN0D
|
Valrubicin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vandetanib + FORMESTANE
|
DCGJ81F
|
Vandetanib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vandetanib + FORMESTANE
|
DCGTBKX
|
Vandetanib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vandetanib + FORMESTANE
|
DCQCLQA
|
Vandetanib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vandetanib + FORMESTANE
|
DCTH5TV
|
Vandetanib
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vandetanib + FORMESTANE
|
DCAIT8R
|
Vandetanib
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vandetanib + FORMESTANE
|
DCIWDOG
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vandetanib + FORMESTANE
|
DCXI4F7
|
Vandetanib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vandetanib + FORMESTANE
|
DCH8EK8
|
Vandetanib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vandetanib + FORMESTANE
|
DCRGCYH
|
Vandetanib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vandetanib + FORMESTANE
|
DCY5AKK
|
Vandetanib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCIIUNJ
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Vemurafenib + FORMESTANE
|
DCW842T
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Vemurafenib + FORMESTANE
|
DCR1JOD
|
Vemurafenib
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCVG1M7
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCMGL39
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCZG6HB
|
Vemurafenib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCEBDNR
|
Vemurafenib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCAFHRG
|
Vemurafenib
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DC2IBNR
|
Vemurafenib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCR1QG2
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCMJLME
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCCF4WH
|
Vemurafenib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCMJ4R1
|
Vemurafenib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCD8VWQ
|
Vemurafenib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + FORMESTANE
|
DCDR3JE
|
Vemurafenib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vincristine + FORMESTANE
|
DCAJ727
|
Vincristine
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Vincristine + FORMESTANE
|
DC51J33
|
Vincristine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Vincristine + FORMESTANE
|
DCVB7CL
|
Vincristine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Vincristine + FORMESTANE
|
DCFCG7U
|
Vincristine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Vinflunine + FORMESTANE
|
DCIRC6E
|
Vinflunine
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Vinflunine + FORMESTANE
|
DCUSS8J
|
Vinflunine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
Vinflunine + FORMESTANE
|
DC2KW6N
|
Vinflunine
|
Glioma (Cell Line: SF-295)
|
[4] |
|
Vinflunine + FORMESTANE
|
DC2UVXV
|
Vinflunine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vinflunine + FORMESTANE
|
DCCVVGI
|
Vinflunine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Vinflunine + FORMESTANE
|
DC9OVKE
|
Vinflunine
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Vinflunine + FORMESTANE
|
DC165LC
|
Vinflunine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vinflunine + FORMESTANE
|
DC5VS0R
|
Vinflunine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vinflunine + FORMESTANE
|
DCCXHOB
|
Vinflunine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vismodegib + FORMESTANE
|
DCVLV76
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Vismodegib + FORMESTANE
|
DC5V53V
|
Vismodegib
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vismodegib + FORMESTANE
|
DCC5WEN
|
Vismodegib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Vismodegib + FORMESTANE
|
DC25GT6
|
Vismodegib
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vismodegib + FORMESTANE
|
DC21X2U
|
Vismodegib
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Vismodegib + FORMESTANE
|
DCGN6JN
|
Vismodegib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vismodegib + FORMESTANE
|
DCQCZQ2
|
Vismodegib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vismodegib + FORMESTANE
|
DCKB1DP
|
Vismodegib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Vismodegib + FORMESTANE
|
DC3E17W
|
Vismodegib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vismodegib + FORMESTANE
|
DCD2PE1
|
Vismodegib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vismodegib + FORMESTANE
|
DC8RKR8
|
Vismodegib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
